Neuland Laboratories: The Financial Results of the Company for the quarter and half year ended September 30, 2026
Neuland Laboratories (NEULANDLAB) filed a disclosure titled "The Financial Results of the Company for the quarter and half year ended September 30, 2026". The company is valued at about ₹25,115 crore.
What happened
Neuland Laboratories (NEULANDLAB) filed a disclosure with the exchanges on 3 November 2026 at 04:15 PM titled "The Financial Results of the Company for the quarter and half year ended September 30, 2026".
Company snapshot
Neuland Laboratories is a small-cap company in the Healthcare sector, with a market value of about ₹25,115 crore.
The stock last traded at ₹19,575, against a 52-week range of ₹11,500–₹24,225 (19.2% below the high).
Before this filing the shares had moved −8.3% over the month and −0.5% over three months. Average daily turnover over the last 20 sessions was about ₹89.09 crore.
Promoters held 32.62% at the end of Q1 FY27, down 0.01% points from the previous quarter; 2.29% of promoter shares were pledged. Foreign institutions owned 21.08% and domestic institutions 16.51%.
| Quarter | Revenue | Net profit | EPS (₹) |
|---|---|---|---|
| Q1 FY26 | 293 | 13.9 | 10.83 |
| Q2 FY26 | 514 | 96.9 | 75.49 |
| Q3 FY26 | 440 | 40.6 | 31.62 |
| Q4 FY26 | 776 | 212.7 | 165.76 |
| Q1 FY27 | 642 | 147.7 | 115.1 |
What history shows
BCEIE's records show 4 previous results filings from the company since May 2026.
After those filings, the stock gained 14.5% on average the next trading day and was up 16.3% on average after five days (2 filings with price data).
Across 300 similar disclosures by other Healthcare companies, shares moved +1.2% on average the next day and +1.7% over five days; 56% of them rose the next day.
Market-wide, 10,321 results filings with an impact score of 50 or more saw an average next-day move of −0.3%, with 42% rising.
Past reactions describe what happened before; they are not a forecast.
| Date | Filing | Next day | 5 days |
|---|---|---|---|
| 5 Aug 2026 | Unaudited Financial Results Of The Company For The Quarter Ended… | +14.5% | +16.3% |
| 5 Aug 2026 | Board Meeting Outcome for Unaudited Financial Results Of The Company… | +14.5% | +16.3% |
What to watch
- Management commentary, margins and order book or guidance in the investor presentation.
- 3 November 2026: Board meeting — Financial Results.
In the news
Recent coverage elsewhere (links open the original publisher):
- Neuland Laboratories: Betting On New Growth Avenues
- Neuland Laboratories Share Price Today: Price Fall Analysis
- Neuland Laboratories (NEULANDLAB.NS) Jumps 3.39% to ₹19,970 — CDMO Counter Approaches Key Resistance - Collar Trade
- Neuland Laboratories NEULANDLAB Special Window Physical Shares
- Neuland Laboratories Q2 FY27 Earnings Call Date and Details
Source
Automatically written from the exchange filing and BCEIE data. Not investment advice. Check the original filing before acting on it.